Welcome to our dedicated page for Regeneron Pharmaceuticals SEC filings (Ticker: REGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Regeneron Pharmaceuticals Inc. filings document the regulatory disclosures of a biotechnology operating company with marketed medicines, clinical programs and collaboration-driven research activity. Recent Form 8-K reports furnish quarterly and annual financial and operating results, including GAAP and non-GAAP measures, product sales commentary, regulatory and pipeline updates, and acquired in-process research and development charges tied to collaboration, licensing and asset-acquisition activity.
The company's proxy materials cover governance and executive compensation matters, including pay-versus-performance data and equity award disclosures. Regeneron's SEC record also includes exhibit filings and Inline XBRL cover-page data associated with material-event reports, providing formal documentation of financial reporting, corporate governance and capital-allocation disclosures such as share repurchase authorization.
Regeneron Pharmaceuticals’ VP Controller reported new equity awards and related share movements. On December 5, 2025, the officer received 2,064 shares of common stock at $0.0 per share as restricted stock under the Second Amended and Restated 2014 Long-Term Incentive Plan, vesting 50% on December 5, 2027 and 50% on December 5, 2029. The same day, the officer was granted a non-qualified stock option for 2,261 shares of common stock with an exercise price of $726.71 per share, expiring on December 5, 2035 and vesting in four equal annual installments beginning one year after the grant date.
On December 8, 2025, the filing shows a disposition of 989 shares of common stock at $712.94 per share. Following these transactions, the officer directly owns 5,308 common shares, with additional indirect holdings of 31 shares through a 401(k) plan and 179 shares held by a spouse, along with the 2,261 stock options.
Regeneron Pharmaceuticals (REGN) executive Joseph LaRosa reported a stock option exercise and share transactions. On 11/20/2025, he exercised a non-qualified stock option for 14,450 shares of common stock at an exercise price of $555.67 per share. On the same date, 12,686 shares were disposed of in a transaction reported at $736.77 per share, which is typically associated with covering taxes or similar obligations.
Following these transactions, LaRosa directly beneficially owned 22,839 shares of Regeneron common stock. He also indirectly owned 9,000 shares through a 2024 GRAT, 9,000 shares through a 2025 GRAT, and 395 shares through a 401(k) plan. The option award referenced in the filing vested in four equal annual installments starting one year after the grant date and is now fully exercised, with zero derivative securities remaining from this grant.
Regeneron Pharmaceuticals (REGN) director reports stock option exercise and sale. On 11/20/2025, the reporting person exercised a non-qualified stock option for 760 shares of common stock at an exercise price of $371.4 per share and then sold 760 shares of common stock at a price of $750 per share. After these transactions, the director beneficially owned 1,548 shares of Regeneron common stock directly and 756 non-qualified stock options. The transactions were made under a Rule 10b5-1(c) trading plan adopted on May 2, 2025.
Regeneron Pharmaceuticals (REGN) reported an insider transaction on Form 4. The company’s VP Controller sold 431 shares of common stock at $651.43 per share on 11/07/2025 (transaction code S). Following the sale, the reporting person beneficially owns 4,233 shares directly, plus 31 shares held by a 401(k) plan and 179 shares held by a trust. This filing documents a routine change in personal holdings and does not alter the company’s capital structure.
REGENERON PHARMACEUTICALS, INC. filed a Form 13F reporting institutional holdings totaling $700,444,832. The filing lists 4 information-table entries and was submitted as a 13F Holdings Report by the reporting manager. The report certifies the information is true and complete and is signed by Leonard Brooks, Senior Vice President, Treasurer.
Regeneron Pharmaceuticals (REGN) director Christine A. Poon reported insider transactions. On 10/29/2025, she exercised 6,500 non-qualified stock options at $520.01 and sold shares in multiple trades: 650 at $652.68, 2,735 at $653.5, 1,915 at $654.42, 100 at $655.1, 712 at $656.5, and 388 at $657.29.
On 10/30/2025, she exercised an additional 2,712 options at $520.01. Following the reported transactions, she beneficially owned 5,064 shares, held directly.
Regeneron Pharmaceuticals (REGN) executive Andrew Murphy reported insider transactions. On 10/29/2025, he exercised 35,000 non‑qualified stock options at $555.67 per share (code M), acquiring common stock. To cover taxes, 32,490 shares were withheld at $648.82 (code F). On 10/30/2025, he made a bona fide gift of 1,538 shares (code G).
After these transactions, he beneficially owned 50,046 shares directly and 4,370 shares indirectly via a 401(k) plan. The exercised option, which was scheduled to expire on 12/16/2025 and vested in four annual installments, now has 0 remaining.
Regeneron Pharmaceuticals reported Q3 2025 results. Revenue was $3,754.3 million, slightly above last year’s $3,720.7 million. Net income rose to $1,460.0 million with diluted EPS of $13.62, up from $11.54.
Product sales softened while collaboration income grew. Net product sales were $1,587.7 million versus $1,946.4 million, reflecting lower U.S. EYLEA family sales ($1,111.2 million vs $1,536.9 million) and higher global Libtayo sales ($365.2 million vs $288.6 million). Collaboration revenue increased to $1,968.4 million from $1,660.1 million, including contributions from Sanofi and Bayer.
Year-to-date operating cash flow reached $3,808.2 million. The company repurchased 1.1 million shares in Q3 for $663.0 million (4.5 million shares for $2,785.3 million year-to-date) and declared a $0.88 quarterly dividend in October. Total assets were $40,169.4 million and stockholders’ equity was $30,957.8 million as of September 30, 2025.
Regeneron Pharmaceuticals (REGN) furnished a press release reporting financial and operating results for the quarter ended September 30, 2025.
The press release is attached as Exhibit 99.1 and incorporated by reference into Item 2.02. The company states this information is furnished, not filed, under the Exchange Act and is not incorporated into Securities Act filings unless specifically referenced.
Regeneron Pharmaceuticals expects to record an acquired in-process research and development charge of approximately $83 million on a pre-tax basis in its GAAP and non-GAAP financial results for the third quarter of 2025. This charge primarily reflects a previously disclosed $80 million up-front payment to Hansoh Pharmaceuticals Group Company Limited under a 2025 license agreement.
The acquired IPR&D charge is expected to reduce both GAAP and non-GAAP net income per diluted share for the third quarter of 2025 by approximately $0.68. Regeneron notes that it does not forecast acquired IPR&D charges because the timing and size of such transactions are uncertain, and it emphasizes that third-quarter 2025 results are preliminary and subject to completion of normal closing procedures.